Rad51 and BRCA2 - new molecular targets for sensitizing glioma cells to alkylating anticancer drugs

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Quiros, Steve ^a   Roos, Wynand Paul ^a   Kaina, Bernd ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

6 O ALKYLGUANINE; ALKYLATING AGENT; BRCA2 PROTEIN; GUANINE DERIVATIVE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NIMUSTINE; NU 7026; OLAPARIB; PROTEIN KINASE INHIBITOR; RAD51 PROTEIN; SMALL INTERFERING RNA; TEMOZOLOMIDE; UNCLASSIFIED DRUG; 2 (MORPHOLIN 4 YL)BENZO(H)CHROMEN 4 ONE; 2-(MORPHOLIN-4-YL)BENZO(H)CHROMEN-4-ONE; CHROMONE DERIVATIVE; MORPHOLINE DERIVATIVE; RAD51 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DEATH; CONTROLLED STUDY; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; DRUG SENSITIVITY; DRUG SENSITIZATION; DRUG TARGETING; ENZYME INHIBITION; GENE SILENCING; GENETIC RECOMBINATION; GLIOMA CELL; HOMOLOGOUS RECOMBINATION; IONIZING RADIATION; MOLECULARLY TARGETED THERAPY; NON HOMOLOGOUS END JOINING; PROTEIN DEPLETION; PROTEIN EXPRESSION; RNA INTERFERENCE; APOPTOSIS; BRAIN TUMOR; DNA DAMAGE; DRUG EFFECT; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GLIOMA; HUMAN; NUCLEOTIDE SEQUENCE; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BASE SEQUENCE; BRAIN NEOPLASMS; BRCA2 PROTEIN; CELL LINE, TUMOR; CHROMONES; DNA DAMAGE; FLOW CYTOMETRY; GLIOMA; HOMOLOGOUS RECOMBINATION; HUMANS; MICROSCOPY, FLUORESCENCE; MORPHOLINES; PROTEIN KINASE INHIBITORS; RAD51 RECOMBINASE; RNA, SMALL INTERFERING;

EID: 80355123699     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027183     Document Type: Article

References (34)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996.
2. Kaina B, Christmann M, Naumann S, Roos WP, (2007) MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst) 6: 1079-1099.
3. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003.
4. Christmann M, Nagel G, Horn S, Krahn U, Wiewrodt D, et al. (2010) MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma. Int J Cancer 127: 2106-2118.
5. Kaina B, Margison GP, Christmann M, (2010) Targeting O-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. Cell Mol Life Sci 67: 3663-3681.
6. Karran P, Bignami M, (1994) DNA damage tolerance, mismatch repair and genome instability. Bioessays 16: 833-839.
7. Ochs K, Kaina B, (2000) Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent. Cancer Res 60: 5815-5824.
8. Mojas N, Lopes M, Jiricny J, (2007) Mismatch repair-dependent processing of methylation damage gives rise to persistent single-stranded gaps in newly replicated DNA. Genes Dev 21: 3342-3355.
9. Quiros S, Roos WP, Kaina B, (2010) Processing of O6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles. Cell Cycle 9: 168-178.
10. Roos WP, Batista LF, Naumann SC, Wick W, Weller M, et al. (2007) Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 26: 186-197.
11. Weterings E, Chen DJ, (2008) The endless tale of non-homologous end-joining. Cell Res 18: 114-124.
12. Lieber MR, (2010) The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem 79: 181-211.
13. San Filippo J, Sung P, Klein H, (2008) Mechanism of eukaryotic homologous recombination. Annu Rev Biochem 77: 229-257.
14. Li X, Heyer WD, (2008) Homologous recombination in DNA repair and DNA damage tolerance. Cell Res 18: 99-113.
15. Jensen RB, Carreira A, Kowalczykowski SC, (2010) Purified human BRCA2 stimulates RAD51-mediated recombination. Nature 467: 678-683.
16. Liu J, Doty T, Gibson B, Heyer WD, (2010) Human BRCA2 protein promotes RAD51 filament formation on RPA-covered single-stranded DNA. Nat Struct Mol Biol 17: 1260-1262.
17. Roos WP, Nikolova T, Quiros S, Naumann SC, Kiedron O, et al. (2009) Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations by a process leading to SCEs. DNA Repair (Amst) 8: 72-86.
18. Beranek DT, (1990) Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents. Mutat Res 231: 11-30.
19. Nikolova T, Ensminger M, Lobrich M, Kaina B, (2010) Homologous recombination protects mammalian cells from replication-associated DNA double-strand breaks arising in response to methyl methanesulfonate. DNA Repair (Amst) 9: 1050-1063.
20. Citron M, White A, Decker R, Wasserman P, Li B, et al. (1995) O6-methylguanine-DNA methyltransferase in human brain tumors detected by activity assay and monoclonal antibodies. Oncol Res 7: 49-55.
21. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM, (1998) DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273: 5858-5868.
22. Rodrigue A, Lafrance M, Gauthier MC, McDonald D, Hendzel M, et al. (2006) Interplay between human DNA repair proteins at a unique double-strand break in vivo. EMBO J 25: 222-231.
23. Willmore E, de Caux S, Sunter NJ, Tilby MJ, Jackson GH, et al. (2004) A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood 103: 4659-4665.
24. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, et al. (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913-917.
25. Boudreau RL, Davidson BL, (2010) RNAi therapeutics for CNS disorders. Brain Res 1338: 112-121.
26. Bowers WJ, Breakefield XO, Sena-Esteves M, (2011) Genetic therapy for the nervous system. Hum Mol Genet 20: R28-41.
27. Koch D, Hundsberger T, Boor S, Kaina B, (2007) Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma. J Neurooncol 82: 85-89.
28. Weller M, Rieger J, Grimmel C, Van Meir EG, De Tribolet N, et al. (1998) Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses. Int J Cancer 79: 640-644.
29. Batista LF, Roos WP, Christmann M, Menck CF, Kaina B, (2007) Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks. Cancer Res 67: 11886-11895.
30. Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, et al. (2006) O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 96: 766-776.
31. Biard DS, (2007) Untangling the relationships between DNA repair pathways by silencing more than 20 DNA repair genes in human stable clones. Nucleic Acids Res 35: 3535-3550.
32. Kaina B, Fritz G, Mitra S, Coquerelle T, (1991) Transfection and expression of human O6-methylguanine-DNA methyltransferase (MGMT) cDNA in Chinese hamster cells: the role of MGMT in protection against the genotoxic effects of alkylating agents. Carcinogenesis 12: 1857-1867.
33. Fan S, Meng Q, Auborn K, Carter T, Rosen EM, (2006) BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells. Br J Cancer 94: 407-426.
34. Shao CJ, Fu J, Shi HL, Mu YG, Chen ZP, (2008) Activities of DNA-PK and Ku86, but not Ku70, may predict sensitivity to cisplatin in human gliomas. J Neurooncol 89: 27-35.